Entellus Medical (NASDAQ:ENTL) was upgraded by equities researchers at TheStreet from a “d” rating to a “c-” rating in a research report issued to clients and investors on Thursday.

Several other research analysts have also recently weighed in on the stock. Piper Jaffray Companies restated a “buy” rating and set a $21.00 price target on shares of Entellus Medical in a report on Tuesday, August 22nd. BidaskClub upgraded shares of Entellus Medical from a “hold” rating to a “buy” rating in a report on Saturday, August 19th. Zacks Investment Research upgraded shares of Entellus Medical from a “sell” rating to a “buy” rating and set a $23.00 price target on the stock in a report on Monday, October 9th. ValuEngine upgraded shares of Entellus Medical from a “sell” rating to a “hold” rating in a report on Thursday, December 7th. Finally, Canaccord Genuity restated a “hold” rating and set a $17.00 price target on shares of Entellus Medical in a report on Tuesday, October 17th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and two have given a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $20.40.

Shares of Entellus Medical (NASDAQ ENTL) opened at $24.63 on Thursday. The company has a current ratio of 1.92, a quick ratio of 1.71 and a debt-to-equity ratio of 0.32. Entellus Medical has a 52-week low of $11.47 and a 52-week high of $24.88.

In other Entellus Medical news, Director Brian E. Farley sold 101,319 shares of the business’s stock in a transaction dated Thursday, December 7th. The shares were sold at an average price of $23.85, for a total value of $2,416,458.15. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, VP Timothy B. Petrick sold 2,000 shares of the business’s stock in a transaction dated Friday, September 22nd. The shares were sold at an average price of $18.00, for a total transaction of $36,000.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 168,469 shares of company stock worth $3,718,611. Corporate insiders own 7.70% of the company’s stock.

Several hedge funds have recently made changes to their positions in ENTL. Aisling Capital LLC purchased a new stake in shares of Entellus Medical during the 3rd quarter valued at approximately $9,759,000. Frontier Capital Management Co. LLC lifted its stake in shares of Entellus Medical by 85.0% during the 2nd quarter. Frontier Capital Management Co. LLC now owns 866,370 shares of the medical technology company’s stock valued at $14,347,000 after buying an additional 397,953 shares in the last quarter. Tekla Capital Management LLC purchased a new stake in shares of Entellus Medical during the 2nd quarter valued at approximately $5,655,000. Nicholas Company Inc. lifted its stake in shares of Entellus Medical by 1,052.3% during the 2nd quarter. Nicholas Company Inc. now owns 247,685 shares of the medical technology company’s stock valued at $4,101,000 after buying an additional 226,190 shares in the last quarter. Finally, Vanguard Group Inc. lifted its stake in shares of Entellus Medical by 77.8% during the 1st quarter. Vanguard Group Inc. now owns 424,823 shares of the medical technology company’s stock valued at $5,862,000 after buying an additional 185,833 shares in the last quarter. Institutional investors own 78.76% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece of content was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2017/12/16/entellus-medical-entl-rating-increased-to-c-at-thestreet.html.

About Entellus Medical

Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.

Analyst Recommendations for Entellus Medical (NASDAQ:ENTL)

Receive News & Ratings for Entellus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical and related companies with MarketBeat.com's FREE daily email newsletter.